Hormonal therapy, contraception, and infertility drugs are central to managing reproductive health across the lifespan. These medications control menopausal symptoms, prevent pregnancy, and support fertility, so nurses need a solid grasp of how they work, their side effects, and what to teach patients.
This section covers three drug categories: hormone replacement therapy, contraceptive agents, and ovulation-induction drugs. For each, you'll need to know the mechanism, key side effects, drug interactions, and nursing priorities.
Hormonal Therapy, Contraception, and Infertility Drugs
Key characteristics and uses
Hormonal therapy replaces or supplements the body's own estrogen and progesterone when levels decline or become imbalanced.
- Estrogen + progestin combinations are used in hormone replacement therapy (HRT) to treat menopausal symptoms like hot flashes, vaginal dryness, and bone loss from osteoporosis. The combination is used (rather than estrogen alone) in women with an intact uterus because unopposed estrogen raises the risk of endometrial cancer.
- Progestin-only medications manage endometriosis, abnormal uterine bleeding, and can also serve as contraception.
Contraceptive drugs prevent pregnancy through several overlapping mechanisms.
- Combined oral contraceptives (COCs) contain both estrogen and progestin. They work primarily by suppressing ovulation, but also thicken cervical mucus (blocking sperm) and thin the endometrial lining (reducing the chance of implantation).
- Progestin-only pills (POPs), sometimes called the "mini-pill," are appropriate for breastfeeding women or those with contraindications to estrogen (e.g., history of blood clots, migraines with aura). They mainly thicken cervical mucus and may suppress ovulation inconsistently.
- Long-acting reversible contraceptives (LARCs) include hormonal IUDs (e.g., Mirena, which releases levonorgestrel) and subdermal implants (e.g., Nexplanon). These are among the most effective contraceptive methods because they don't depend on daily patient adherence.
Infertility drugs stimulate ovulation in women who aren't ovulating regularly.
- Clomiphene citrate (Clomid) is typically the first-line agent for ovulation induction, especially in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders. It's taken orally, usually on cycle days 5–9.
- Gonadotropins (injectable FSH and LH preparations like Follistim or Menopur) directly stimulate the ovaries to develop follicles. These are used in assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) and carry a higher risk of ovarian hyperstimulation.
Mechanisms, side effects, interactions
Mechanisms of action
- Estrogen promotes development and maintenance of female secondary sexual characteristics (breast tissue, fat distribution) and plays a role in the menstrual cycle by stimulating endometrial growth during the proliferative phase.
- Progestin prepares the uterus for potential implantation by stabilizing and thickening the endometrium. It also reduces uterine contractions, which helps maintain early pregnancy.
- Clomiphene citrate is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus, which tricks the body into thinking estrogen levels are low. The hypothalamus responds by increasing GnRH release, which in turn boosts FSH and LH secretion from the anterior pituitary, stimulating follicle growth and ovulation.
Potential side effects
- Hormonal therapy (HRT): breast tenderness, nausea, headaches, bloating, and an increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism). Long-term use has also been associated with increased breast cancer risk.
- Contraceptives: irregular or breakthrough bleeding (especially in the first 1–3 months), weight changes, mood alterations, decreased libido, and headaches. COCs specifically carry a dose-dependent risk of venous thromboembolism (VTE).
- Infertility drugs: hot flashes, mood swings, and headaches with clomiphene. Gonadotropins carry a risk of ovarian hyperstimulation syndrome (OHSS), which can range from mild bloating and discomfort to severe fluid shifts, ascites, and in rare cases, renal failure. Multiple gestations (twins, triplets) are also more likely with these drugs.
Drug interactions
These are high-yield for exams. The common thread is that certain drugs increase hepatic metabolism of hormones, reducing their effectiveness.
- Rifampin (an antibiotic used for tuberculosis) is the most clinically significant interaction with oral contraceptives. It induces hepatic enzymes that accelerate estrogen metabolism, potentially causing contraceptive failure. Note: most other common antibiotics (like amoxicillin) do not have strong evidence for reducing COC efficacy, despite the widespread belief.
- Antiepileptic drugs such as carbamazepine, phenytoin, and phenobarbital are CYP450 enzyme inducers that increase the breakdown of estrogens and progestins, reducing hormonal contraceptive effectiveness.
- St. John's Wort, an herbal supplement used for mild depression, also induces CYP450 enzymes (particularly CYP3A4) and can decrease the blood levels of hormonal medications. Always ask patients about herbal supplement use.
Nursing considerations
Assessment
- Review the patient's full medical history for contraindications before starting any hormonal medication. Key red flags include: history of VTE or PE, estrogen-receptor-positive breast cancer, uncontrolled hypertension, liver disease, and unexplained vaginal bleeding.
- Assess modifiable risk factors, particularly smoking. Women over 35 who smoke should not use estrogen-containing contraceptives due to significantly elevated cardiovascular risk.
- Evaluate the patient's understanding of the medication, expected effects, and potential risks to support truly informed consent.
Administration
- COCs should be taken at the same time every day. A missed pill increases the risk of breakthrough ovulation. Teach patients what to do if a dose is missed (this varies by how many pills were missed and which week of the pack).
- For injectable contraceptives like Depo-Provera (medroxyprogesterone acetate), the injection is given IM every 11–13 weeks. Patients should understand the importance of returning on schedule.
- For infertility drugs, teach proper subcutaneous injection technique for gonadotropins (Follistim, Menopur) if patients will self-administer at home. Verify they can demonstrate correct technique before discharge.
Monitoring
- Watch for breakthrough bleeding in the first few months of COC use; this is common and usually resolves, but persistent bleeding may require a formulation change.
- Monitor for signs of thromboembolic events: unilateral leg swelling, redness, warmth (DVT); sudden chest pain or dyspnea (PE). Teach patients to seek emergency care for these symptoms.
- For patients on infertility drugs, monitor for signs of OHSS: rapid weight gain, abdominal distension, nausea/vomiting, decreased urine output. Mild cases are managed conservatively; severe cases require hospitalization.
- Track treatment response: return of regular menstrual cycles with HRT, absence of pregnancy with contraceptives, or evidence of ovulation (ultrasound monitoring, serum progesterone levels) with fertility drugs.
Collaboration
- Work with prescribers to develop individualized treatment plans based on patient goals, preferences, and risk profile.
- Refer to reproductive endocrinologists when first-line infertility treatments fail or when advanced procedures (IVF, intracytoplasmic sperm injection) are indicated.
Client education plan
Proper usage
- Provide clear, specific instructions on administration route and timing. For transdermal patches (e.g., Xulane), teach proper placement on clean, dry skin and weekly rotation schedule.
- Stress that consistent daily timing is critical for contraceptive efficacy, especially with POPs, which have a narrower window (must be taken within the same 3-hour window each day).
- During the first month of COC use, advise patients to use a backup method (condoms) since full contraceptive effect may not be established immediately.
Expectations
- With clomiphene, ovulation typically occurs 5–10 days after the last dose. Patients should understand that it may take several cycles to achieve pregnancy.
- IVF success rates vary by age: roughly 40–50% per cycle for women under 35, declining significantly after age 40. Set realistic expectations early.
- HRT symptom relief (especially for hot flashes) usually begins within a few weeks but may take up to 3 months for full effect.
Potential concerns
- Address the common myth that COCs cause long-term infertility. Fertility typically returns within 1–3 months of discontinuation.
- Discuss the risk of multiple pregnancies with gonadotropin therapy. This is why close ultrasound monitoring of follicle development is standard during treatment.
- Instruct patients to report severe pelvic pain, sudden vision changes, severe headaches, or signs of blood clots immediately.
Follow-up
- Schedule regular check-ins to assess treatment progress, manage side effects, and adjust dosages as needed (e.g., changing HRT formulation if breakthrough bleeding persists).
- For patients undergoing infertility treatment, provide resources for emotional support. Organizations like RESOLVE: The National Infertility Association offer support groups and educational materials. Acknowledge that the process can be emotionally taxing, and connect patients with counseling services when appropriate.